SAINT LAURENT, QUEBEC (MARKET WIRE) IntelGenx Corp. (TSX VENTURE: IGX)(OTCBB: IGXT) ("IntelGenx", or "the Company"), announced that it has executed a binding term-sheet with RedHill Biopharma Ltd. ("RedHill"), an Israeli corporation listed on the Tel Aviv Stock Exchange ("TASE") under the symbol RDHL, to co-develop and license an anti-psychotic oral thin film product based upon the Company's proprietary VersaFilm technology.